Abstract

ADVANCES IN PROTAC DRUG DELIVERY SYSTEMS: BRIDGING TARGETED PROTEIN DEGRADATION AND PRECISION MEDICINE

Ms. Nehe Ashwini Rajaram, *Mr. Hule Dnyaneshwar Kisan

ABSTRACT

Proteolysis Targeting Chimeras (PROTACs) are a new therapeutic approach that uses the cell’s natural ubiquitin-proteasome system to selectively break down disease-causing proteins. Unlike traditional inhibitors, PROTACs provide long-lasting and catalytic protein reduction, making them very promising for treating targets that were previously hard to approach with drugs. However, their use in clinics is still limited due to issues like poor solubility, large size, low ability to cross membranes, and less effective drug action in the body. To tackle these challenges, new drug delivery systems are being created to improve PROTAC stability, availability, and targeted delivery. Modern nanocarriers, such as liposomes, polymeric nanoparticles, micelles, and lipid-based systems, have shown significant potential in boosting treatment effectiveness while minimizing off-target effects. This reviewlooks at recent advancements and design strategies in PROTAC drug delivery, focusing on nanotechnology-driven platforms and systems that respond to stimuli for precise release within cells. Additionally, emerging trends and future insights emphasize the important role of delivery innovations in moving PROTACs from the lab to clinical use, opening a new chapter in precision medicine.

Keywords: PROTACs, targeted protein degradation, nanocarriers, drug delivery, precision medicine, nanotechnology.